慢性乙型肝炎疾病进展性别差异的机制研究进展

摘要/Abstract

摘要： 慢性乙型肝炎(CHB)是全球范围内重要的公共卫生问题。我国人口基数大,乙型肝炎病毒的感染人数位居全球之首,且男性乙型肝炎病毒感染率高于女性。这种性别差异不仅体现在疾病的易感性上,还体现在疾病的进展过程中。多项研究表明,男性CHB患者比女性更容易发展为严重的肝脏疾病,如肝硬化和肝细胞癌。近年来,性别相关因素对CHB发生与发展的影响备受关注,本文系统综述了性别相关因素对CHB患者疾病进展差异的影响,深入探讨其潜在机制,旨在为临床医师基于性别制订个体化治疗方案及防控策略提供理论依据。

关键词: 慢性乙型肝炎, 疾病进展, 性别差异, 性激素, 性激素受体

代依婷, 蔡大川. 慢性乙型肝炎疾病进展性别差异的机制研究进展[J]. 肝脏, 2026, 31(4): 586-591.

/ 推荐

参考文献

[1] Yan R, Sun M, Yang H, et al. 2024 latest report on hepatitis B virus epidemiology in China: current status,changing trajectory,and challenges[J]. Hepatobiliary Surg Nutr,2025, 14(1): 66-77.
[2] Xu Y,Xia C,Li H,et al. Survey of hepatitis B virus infection for liver cancer screening in China: a population-based,cross-sectional study[J]. Chin Med J (Engl),2024,137(12): 1414-1420.
[3] Meng Z,Ma Z,Zhang E,et al. Novel woodchuck hepatitis virus (WHV) transgene mouse models show sex-dependent WHV replicative activity and development of spontaneous immune responses to WHV proteins[J]. J Virol,2014,88(3): 1573-1581.
[4] 徐小倩,王皓,单姗,等.中国慢性乙型肝炎临床特征和抗病毒治疗模式十年变迁:基于CR-HepB的真实世界研究[J]. 中华肝脏病杂志,2023,31(7) : 698-704.
[5] Han B,Zheng R,Zeng H,et al. Cancer incidence and mortality in China,2022[J]. J Natl Cancer Cent,2024,4(1): 47-53.
[6] Graham S,MacLachlan J H,Gunaratnam P,et al. Chronic hepatitis B prevalence in Australian aboriginal and torres strait islander people before and after implementing a universal vaccination program: a systematic review and meta-analysis[J]. Sex Health,2019,16(3): 201-211.
[7] Wu X N,Xue F,Zhang N,et al. Global burden of liver cirrhosis and other chronic liver diseases caused by specific etiologies from 1990 to 2019[J]. BMC Public Health,2024,24: 363.
[8] 张希,杨雷,刘硕,等 . 2022全球恶性肿瘤统计报告解读[J]. 中华肿瘤杂志 ,2024,46(7):710-721.
[9] 中华医学会肝病学分会,中华医学会感染病学分会 .慢性乙型肝炎防治指南(2022年版)[J].中华肝脏病杂志,2022,30(12):1309-1331.
[10] Dou D R,Zhao Y,Belk J A,et al. Xist ribonucleoproteins promote female sex-biased autoimmunity[J]. Cell,2024,187(3): 733-749.e16.
[11] Kido T,Lo R C lam,Li Y,et al. The potential contributions of a Y-located protooncogene and its X homologue in sexual dimorphisms in hepatocellular carcinoma[J]. Hum Pathol,2014,45(9): 1847-1858.
[12] Xie J,Ding Y,Li X,et al. Association of ESR1 gene polymorphisms with the susceptibility to Hepatitis B virus infection and the clinical outcomes[J]. J Med Virol,2023,95(2): e28510.
[13] Xu B Y,Tan W T,Tan S,et al. Serum testosterone levels and androgen receptor CAG polymorphism correlate with hepatitis B virus (HBV)-related acute liver failure in male HBV carriers[J]. PLoS One,2013,8(12): e84213.
[14] Duan H,Wang X,Qi W,et al. Two genetic variants in the SRD5A2 gene are found to be associated with sex differences in the disease characteristics of patients with chronic hepatitis B virus infection[J]. Biol Sex Differ,2023,4(1): 68.
[15] Park H J,Choi J M. Sex-specific regulation of immune responses by PPARs[J]. Exp Mol Med, 2017,49(8): e364.
[16] Li M,Zhao Y,Chen X,et al. Contribution of sexbased immunological differences to the enhanced immune response in female mice following vaccination with hepatitis B vaccine[J]. Mol Med Rep,2019.
[17] Klein S L. Sex influences immune responses to viruses,and efficacy of prophylaxis and treatments for viral diseases[J]. BioEssays,2012,34(12): 1050-1059.
[18] Spolarics Z,Peña G,Qin Y,et al. Inherent X-linked genetic variability and cellular mosaicism unique to females contribute to sex-related differences in the innate immune response[J]. Front Immunol,2017,8: 1455.
[19] Kosinska A D,Pishraft-Sabet L,Wu W,et al. Low hepatitis B virus-specific T-cell response in males correlates with high regulatory T-cell numbers in murine models[J]. Hepatology,2017, 66(1): 69-83.
[20] Naugler W E,Sakurai T,Kim S,et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production[J]. Science,2007,317(5834): 121-124.
[21] Gandhi N,Oturkar C C,Das G M. Estrogen receptor-alpha and p53 status as regulators of AMPK and mTOR in luminal breast cancer[J]. Cancers (Basel),2021,13(14): 3612.
[22] Trigunaite A,Dimo J,Jørgensen T N. Suppressive effects of androgens on the immune system[J]. Cell Immunol,2015,294(2): 87-94.
[23] Zhou J,Liu M,Sun H,et al. Hepatoma-intrinsic CCRK inhibition diminishes myeloid-derived suppressor cell immunosuppression and enhances immune-checkpoint blockade efficacy[J]. Gut,2018,67(5): 931-944.
[24] Shi L,Lin H,Li G,et al. Cisplatin enhances NK cells immunotherapy efficacy to suppress HCC progression via altering the androgen receptor (AR)-ULBP2 signals[J]. Cancer lett,2016,373(1): 45-56.
[25] Li J,Gao Z,Bai H,et al. Global,regional,and national total burden related to hepatitis B in children and adolescents from 1990 to 2021[J]. BMC Public Health,2024,24: 2936.
[26] Simon F R,Fortune J,Iwahashi M,et al. Multihormonal regulation of hepatic sinusoidal ntcp gene expression[J]. Am J Physiol Gastrointest Liver Physiol,2004,287(4): G782-G794.
[27] Shi J,Wang X,Qi W,et al. Association between NTCP hepatic expression and inflammation/fibrosis as well as gender-specific differences in chronic HBV-infected patients[J]. J Med Virol,2024,96(1): e29428.
[28] Qi X,Li W. Unlocking the secrets to human NTCP structure[J]. Innovation (Camb),2022, 3(5): 100294.
[29] Wang S H,Yeh S H,Lin W H,et al. Identification of androgen response elements in the enhancer I of hepatitis B virus: a mechanism for sex disparity in chronic hepatitis B[J]. Hepatology,2009,50(5): 1392-1402.
[30] Wang S,Chen P,Yeh S. Gender disparity in chronic hepatitis B: mechanisms of sex hormones[J]. J Gastroenterol Hepatol,2015,30(8): 1237-1245.
[31] Park E S,Won J,Ahn S H,et al. Gender-specific alteration of steroid metabolism and its impact on viral replication in a mouse model of hepatitis B virus infection[J]. Anim Cells Syst (Seoul),2024,28(1): 466-480.
[32] Wang S,Yeh S,Lin W,et al. Estrogen receptor α represses transcription of HBV genes via interaction with hepatocyte nuclear factor 4α[J]. Gastroenterology,2012,142(4): 989-998.e4.
[33] O’Brien M H,Pitot H C,Chung S H,et al. Estrogen receptor-α suppresses liver carcinogenesis and establishes sex-specific gene expression[J]. Cancers (Basel),2021,13(10): 2355.
[34] Yu Y Y,Li J,Wang W X,et al. Research progress on new drugs for the treatment of chronic hepatitis B virus infection.[J]. Zhonghua Gan Zang Bing Za Zhi,2025,33(5): 493-499.
[35] Lugassy C,Bernuau J,Thiers V,et al. Sequences of hepatitis B virus DNA in the serum and liver of patients with acute benign and fulminant hepatitis[J]. J Infect Dis,1987,155(1): 64-71.
[36] Larsson S B,Tripodi G,Raimondo G,et al. Integration of hepatitis B virus DNA in chronically infected patients assessed by Alu-PCR[J]. J Med Virol,2018,90(10): 1568-1575.
[37] Hui R W H,Wong D K H,Lyu X,et al. Profiles of HBV DNA integration in humans with hepatitis B virus infection: insights for antiviral treatment[J]. JHEP Rep,2025,7(9):101487.
[38] 高田敬,韩耕愚,鲁凤民. 核苷(酸)类药物治疗慢性乙型肝炎患者病毒DNA阴转后发生肝细胞癌的相关机制[J]. 中华肝脏病杂志,2019,27(11): 905-909.
[39] Zhao L H,Liu X,Yan H X,et al. Genomic and oncogenic preference of HBV integration in hepatocellular carcinoma[J]. Nat Commun,2016,7(1): 12992.
[40] Liu W H,Yeh S H,Chen P J. Role of microRNAs in hepatitis B virus replication and pathogenesis[J]. Biochim Biophys Acta,2011,1809(11-12): 678-685.
[41] Li C,Yeh K,Liu W,et al. Elevated p53 promotes the processing of miR-18a to decrease estrogen receptor-α in female hepatocellular carcinoma[J]. Int J Cancer, 2015,136(4): 761-770.
[42] Jiang R,Deng L,Zhao L,et al. miR-22 promotes HBV-related hepatocellular carcinoma development in males[J]. Clin Cancer Res,2011,17(17): 5593-5603.
[43] Chen P J,Yeh S H,Liu W H,et al. Androgen pathway stimulates MicroRNA-216a transcription to suppress the tumor suppressor in lung cancer-1 gene in early hepatocarcinogenesis[J]. Hepatology,2012,56(2): 632-643.
[44] Ouyang X,Feng L,Liu G,et al. Androgen receptor (AR) decreases HCC cells migration and invasion via miR-325/ACP5 signaling[J]. J Cancer,2021,12(7): 1915-1925.
[45] Sartorius K,Wang Y,Sartorius B,et al. The interactive role of microRNA and other non-coding RNA in hepatitis B (HBV) associated fibrogenesis[J]. Funct Integr Genomics,2025,25(1): 24.
[46] Liu M,Zhao T,Zhang Y,et al. The incidence of hepatocellular carcinoma and clearance of hepatitis B surface for CHB patients in the indeterminate phase: a systematic review and meta-analysis[J]. Front Cell Infect Microbiol,2023,13: 1226755.
[47] Shi L,Yan P,Liang Y,et al. Circular RNA expression is suppressed by androgen receptor (AR)-regulated adenosine deaminase that acts on RNA (ADAR1) in human hepatocellular carcinoma[J]. Cell Death Dis,2017,8(11): e3171.